Looking for a new broker?
Impel Pharmaceuticals Inc. stock is up 34.65% since 30 days ago. The next earnings date is Mar 22, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 December’s closed higher than November.
Impel NeuroPharma, Inc. focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is TRUDHESA, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine.
